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ABSTRACT 
Objectives: HIV/1 group P (HIV-1/P) is the last HIV/1 group discovered and to date, comprises 
only two strains. To obtain new insights into this divergent group, we screened for new 
infections by developingspecific tools, and analysed phenotypic and genotypic propertiesof 
theprototypic strain RBF168. In addition, the follow-up of the unique patient monitoredso far, 
has raised the knowledge of the natural history of this infection and its therapeutic management. 
Design/Methods: We developed anHIV-1/Pspecific sero-molecular strategy and screenedover 
29,498specimen samples. Infectivity and evolution of the gag-30 position, considered as marker 
of adaptation to human, were explored by successive passages of RBF168 strain onto human 
PBMCs. Natural history and immuno-virological responses to combined antiretroviral therapy 
(cART) were analysed based on CD4 counts and plasmatic viral load evolution. 
Results: No new infection was detected. Infectivity of RBF168 was found lower, relative to other 
main HIV groups and the conservative methionine found in the gag-30 position revealed a lack 
of adaptation to human. The follow-up of the patient during the five-year ART-free period, 
showed a relative stability of CD4 cell countwith a mean of 326 mm-3. Initiation of cART led to 
rapid RNA undetectability with a significant increase of CD4, reaching 687 mm-3 after 8 years. 
Conclusions: Our resultsshowed that HIV-1/P strains remain extremely rare and could be less 
adapted and pathogenic than other HIV strains. These data lead to the hypothesis that HIV-1/P 
infection could evolve towards, or even already correspond to, a dead-end infection. 
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INTRODUCTION  
Human Immunodeficiency Virus type 1 (HIV-1) is characterized by high genetic diversity, 
classified into 4 groups - M to P [1, 2]; each group results from a separate cross species 
transmission to humans of simian immunodeficiency virus (SIV) found in chimpanzees (SIVcpz) 
or gorillas (SIVgor) [3, 4].  
HIV-1 group P (HIV-1/P), the last group identified, is derived from gorillas [5, 6] and 
represented by only two cases to date. The prototypic strain, RBF168, was reported in a 
Cameroonian woman living in France [6], while the second strain, U14788, was identified in 
retrospective serological screening on specimens collected in Cameroon [7].  
The scarcity of group P infection may be linked to a relatively recent emergence in humans, 
since the time of the most recent common ancestor (tMRCA) of HIV-1/P was estimated, based 
on only two sequences, between the 1950s and 1990s [8]. Another hypothesis is that HIV-1/P 
has distinct virological properties from the other groups, especially HIV-1/M, leading to a 
limited spread. It has been shown that residue replacements of methionine or leucine found at the 
gag-30 position in SIVcpz/SIVgor, by lysine or arginine in the inferred HIV-1 ancestral 
sequences of group M, N and O strains, represent a host-specific adaptation marker [9, 10]. For 
group P, the RBF168 strain harbours methionine, supporting a shared property with simian 
strains, whereas the second strain, U14788, harbours lysine [7]. 
Concerning in vivo features, only limited data from patient RBF168 have been reported [6]. Data 
on immuno-virological response to combined antiretroviral-treatment (cART) were not available, 
while these variants are phylogenetically close to HIV-1/O, harbouring natural polymorphism 
impacting therapeutic management [11]. 
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In order to obtain new insights into HIV-1/P, we screened for new infections, and analysed 
phenotypic and genotypic properties of the prototypic strain RBF168. In addition, the follow-up 
of the unique HIV-1/P positive patient monitored so far, gave unique data on the natural history, 
and on the immuno-virological responses to cART.   
METHODS 
We first defined and validated specific tools for HIV-1/P detection. We adapted a serological 
immunoassay, initially designed to discriminate between HIV-1 groups M, N and O, HIV-2 and 
major SIV lineages [12], by including a group P specific antigen, selected among four candidate 
synthetic oligopeptides (supplementary methods, http://links.lww.com/QAD/B242). To confirm 
group P reactivity, we developed a specific nested RT-PCR, based on the amplification of a 
fragment of 1,110 pb in the gp120 region (supplementary methods, 
http://links.lww.com/QAD/B242).   
We then screened for new HIV-1/P infections among 1,083 samples from collections, for 
which previous results using a serological immunoassay without a P specific antigen were 
inconclusive; they corresponded to: 
- 609 serum/plasma samples received by our laboratory for exploration of atypical 
reactivities at diagnosis time or during the patient’s follow-up.  
- 405 serum/plasma samples from HIV collections from Cameroon and Central 
African Republic, constituted in the 90’s. 
- 69 simian samples   
All samples with reactivity (OD) ≥ 0.500 were first subjected to the group P specific RT-PCR. 
Samples not amplified with the specific RT-PCR were subjected to a nested-RT-PCR (Lentivirus 
PCR) that amplified a 650 pb fragment of pol of HIVs and SIVs (supplementary methods, 
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http://links.lww.com/QAD/B242). Prospective screening was also performed on 28,415 samples, 
diagnosed as HIV positive between March 2013 and June 2015 by the Centre Pasteur of 
Cameroun (CPC), using all the HIV-1 and HIV-2 antigens of the serological immunoassay, as 
previously described [13]. 
We then proceeded to phenotypic and genotypic characterization of the prototypic strain 
RBF168.  The infectivity of the RBF168 strain was analysed after six serial passages in human 
PBMCs by calculating the TCID50 (tissue culture infective dose 50%) as previously described 
[14], and compared to those of seven primary isolates representative of HIV genetic diversity 
(supplementary methods, http://links.lww.com/QAD/B242). To determine the residue evolution 
at gag-30 position during the six passages, we amplified a 493 pb fragment of gag using an in-
house RT-PCR (supplementary methods, http://links.lww.com/QAD/B242). Natural genetic 
polymorphism of the cART targets : protease (PR), reverse transcriptase (RT), integrase (IN), 
and gp41, was also determined on viral RNA from three plasma samples collected before 
treatment initiation (supplementary methods, http://links.lww.com/QAD/B242), and compared to 
that of the second P strain U14788; mutations were subjected to genotypic resistance 
interpretation using the last version (v27) of the ANRS resistance algorithm 
(http://www.hivfrenchresistance.org/). 
Lastly, patient RBF168 was followed up from March 2004 to March 2017; monitoring of CD4 
cell count was performed by Beckman Coulter flow cytometer systems (Beckman, Brea, 
California) and of plasma viral load (pVL) by the RealTime HIV-1 Viral Load assay (Abbott, 
Des Plaines, IL) [6, 15]. 
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RESULTS 
Validation of specific tools led to selection of the candidate peptide CP684 for serological 
screening, and to definition of the analytical sensitivity of the group P specific RT-PCR as close 
to 2 Log cp/mL, with a specificity of 100% (supplementary results, 
http://links.lww.com/QAD/B242). 
Using peptide CP684, 992 of the 1083 (91.6%) samples from the collections were found negative 
(median OD at 0.029), including all the simian samples. Seventy-three (6.7%) gave equivocal 
results (0.1=<OD<0.5), with median OD at 0.146. Eighteen samples corresponding to 14 patients 
(1.6%) were reactive with OD >=0.5 (median at 1.189), six samples being highly reactive from 
1.518 to 2.438. Group P specific RT-PCR performed on samples of these 14 patients gave 
negative results ; the non-specific Lentivirus RT-PCR identified HIV-1/M variants (CRF02_AG, 
n=4 and CRF11-like, n=1), HIV-1/O (n=6), and one dual HIV-1/M+O (data not shown) ; two 
samples were not amplified. Finally, no group P strain was found among the 28,415 HIV positive 
samples diagnosed by the CPC, which were reactive to HIV-1/M (99%), HIV-1/O or HIV-
1/M+O (0.9%), HIV-2 (0.08%) infections, and HIV-1/N (1 case). 
Infectivity testing of the six successive amplifications showed an extremely low median at 261 
TCID50/mL [149; 447], relative to the strains belonging to the other type or groups, especially 
HIV-1/M with a mean TCID50/mL at 250,625 (n=4), while HIV-2 and HIV-1/O showed 
TCID50/mL at 1,171 (n=1) and 22,627 (n=2), respectively. Genotypic characterisation of the 
gag-30 position in each of the six successive amplifications revealed no evolution with 
conservation of methionine.  
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Concerning the cART targets, the natural polymorphism of RBF168 was similar between the 
three sequences before treatment. Based on the ANRS algorithm used to predict genotypic 
resistance of HIV-1/M viruses, the highest number of mutations was detected in the PR with 11 
resistance associated mutations, conferring natural (or possible) resistance to atazanavir, 
tipranavir and saquinavir (table 1). The presence of T69S, A98G, K103R and the atypical 
mutation V179E in the RT, had no genotypic impact (table 1). The IN harboured no resistance 
mutation; but the L44M found in the gp41 led to resistance to enfuvirtide. The genotypic profile 
of strain U14788 was similar to RBF168, leading to the same interpretation (table 1), except for 
the IN, with presence of a T97A mutation leading to genotypic resistance to elvitegravir.  
Monitoring of patient RBF168 started in March 2004 at HIV diagnosis; she did not receive 
cART until December 2008, according to the French guidelines at that time. During this period, 
the mean pVL was at 4.7 Log cp/mL and the mean CD4 count at 326 mm-3, ranging from 260 
(June 2004) to 430 (December 2005) (Figure 1a). In February 2009, cART was initiated with 
tenofovir+emtricitabine+lopinavir/ritonavir, but switched after 2 months to 
abacavir+lamivudine+lopinavir/ritonavir, due to tenofovir adverse effects. This allowed to 
achieve undetectability (<1.6 Log cp/mL) at M3 (Figure 1b), maintained until the last monitoring 
in March 2017 (Figure 1b). During cART, the mean CD4 cell count was at 648 mm-3, with the 
last point at 687 mm-3 in March 2017.  
DISCUSSION 
Only two viral sequences and scarce data on HIV-1/P infection were available until now; thus, 
all new data are needed to improve our knowledge of this group and to assess its potential for 
transmission and pathogenicity.  
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We screened for new infections using a sero-molecular strategy for group P specific detection, as 
previously done for other HIV/SIV variants [12, 13, 16]. After validation of specific tools, we 
tested a large number of samples from collections and prospective diagnosis. Despite a wide 
panel of simian samples or samples with HIV atypical reactivities (profiles similar to that of 
RBF168 at diagnosis), we failed to detect a new HIV-1/P strain. The same is true in older 
collections from central Africa and in the thousands of HIV positive samples, diagnosed 
currently in Cameroon. This confirms that HIV-1 group P infection is extremely rare [2, 7]. 
Reasons for this limited spread are likely multifactorial. In order to better estimate the emergence 
of this group, we performed evolutionary analysis using the two HIV-1/P sequences previously 
analysed [8], and three additional RBF168 sequences (supplementary methods and results, 
http://links.lww.com/QAD/B242). This analysis indicates that HIV-1/P strains share a tMRCA 
dating back to the 1960s. Thus, it would appear that HIV-1/P emerged more recently than strains 
M and O [8], and possibly around the same time period as group HIV-1/N [17]. Another factor 
could be specific viral properties; weak counteracting of human cell restricting factors was 
already demonstrated for tetherin [8]. Focusing on infectivity, our work showed that the serial 
isolates of RBF168 were consistently and reproducibly less infective, in particular relative to 
HIV-1/O (the closest phylogenetic group) and HIV-2 (the lowest pathogenic HIV known so far). 
When searching for residue evolution in gag-30 position, we failed to identify a switch from 
methionine to arginine (harboured by the second P strain, U14788), or lysine (found in other 
HIV-1 variants). However, this evolution probably requires further passages. This apparent lack 
of adaptation of RBF168 to human hosts contrasts with the high replication level in vivo (mean 
pVL at 4.7 Log cp/mL). In this context, it is crucial to screen for other viral determinants of 
adaptation. 
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The follow-up of this single patient during the first five-year ART-free period, showed she 
remained symptom-free, with a relative stability of the CD4 cell count, despite high viral 
replication; this appears similar to the situation encountered in non-pathogenic SIV infections 
harbouring a high level of replication in their symptom-free hosts [18]. The singular natural 
polymorphism of the cART targets (distinct to that of the closest phylogenetic group O), did not 
prevent determination of an efficient therapy, that led to virological success during an 8-year 
follow-up, with a significant increase of CD4 of 600 between nadir and zenith; this suggests no 
difficulty for therapeutic management of this infection.  
In conclusion, we have provided new insights into the last described divergent group. We have 
shown that HIV-1/P strains are extremely rare, suggesting that this variant expanded in a limited 
manner after its recent emergence in the human population, and that subsequently numbers have 
declined. Phenotypic characteristics of the prototypic strain, associated with data on the natural 
course of RBF168 infection, suggest that HIV-1/P could be less adapted and less pathogenic than 
the other HIV-1 strains, accounting for its lack of success in the human population. These 
observations have led to the hypothesis that HIV-1/P infection could evolve towards or even 
already correspond to a dead-end infection.   
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Table 1. Natural polymorphism of RBF168 and U14788 strains in the Protease, Reverse 
Transcriptase, Integrase and gp41.  
 
Region Type of mutation 
Mutations at resistance positions* 
Specific to 
RBF168 
Shared by the two 
strains 
Specific to U14788 
PR 
RAM I15V 
L10V, V11I, L33V, 
M36L, Q58E, D60E, 
I62V, H69R, A71V, 
L89I 
 
Atypical mutation  K20C, L63K,  
Interpretation of mutations 
on drug resistance 
R: saquinavir 
 
R: atazanavir 
I: saquinavir  
 
RT 
RAM  T69S, A98G, K103R  
Atypical mutation  V179E, L210Y K101Q, E138D 
Interpretation of mutations 
on drug resistance 
 No resistance No resistance 
IN 
RAM   T97A 
Interpretation of mutations 
on drug efficacy 
  R:elvitegravir 
gp41 
RAM  L44M  
Interpretation of mutations 
on drugs resistance 
 R: enfuvirtide  
 
RAM: Resistance Associated Mutation, PR: Protease, RT: Reverse Transcriptase IN: Integrase 
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Atypical mutation: mutation not described as associated with resistance, but present at resistance 
position. 
*Mutations found at positions associated with resistance according to the ANRS HIV-1 
genotypic drug resistance interpretation algorithm 2017 v27. 
I: Intermediate, R:Resistant, drugs not mentioned are interpreted as susceptible. 
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